Giulia Costanzo,Giada Sambugaro,Silvio Sartorio et al.
Giulia Costanzo et al.
Introduction: Revolutionary drugs have been developed and approved in the last 5 years for the treatment of hereditary angioedema (HAE). Increased knowledge of HAE pathophysiology has led to the development of innovative ...
Strategies for extending the half-life of biotherapeutics: successes and complications [0.03%]
延长生物治疗药物半衰期的策略：成功与复杂性
Uli Binder,Arne Skerra
Uli Binder
Introduction: Engineering of the drug half-life in vivo has become an integral part of modern biopharmaceutical development due to the fact that many proteins/peptides with therapeutic potential are quickly cleared by kid...
Salim Can,Melek Yorgun Altunbas,Ahmet Ozen
Salim Can
Introduction: CHAPLE disease is a severe, ultra-rare disorder caused by CD55 gene mutations, leading to uncontrolled complement hyperactivation, protein-losing enteropathy, and systemic thrombosis. Recent advances in targ...
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma [0.03%]
伊折沙塞尤克迈( Ide-cel )治疗复发和难治多发性骨髓瘤患者
Katia Mancuso,Simona Barbato,Marco Talarico et al.
Katia Mancuso et al.
Introduction: Modern anti-myeloma therapies have broken new ground in the treatment of the disease, and the incorporation of ide-cel in the treatment landscape represents one of the major scientific and clinical advances....
Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis [0.03%]
莱布利珠单抗：治疗中重度特应性皮炎的新型抗IL-13药物
Luca Stingeni,Silvia Ferrucci,Paolo Amerio et al.
Luca Stingeni et al.
Introduction: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Moderate-to-severe AD severely affects patients' quality of life. New drugs selectively targeting molecular pathways involved in the path...
Karen O Osiro,Nona Hashemi,José Brango-Vanegas et al.
Karen O Osiro et al.
Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors [0.03%]
胆道癌的免疫生物学和已获批及即将问世的免疫检查点抑制剂的最新临床发现
Carmelo Laface,Emanuela Fina,Angela Dalia Ricci et al.
Carmelo Laface et al.
Introduction: Recently, immunotherapy has offered new hope for treating biliary tract cancer (BTC). However, several issues are to be considered, including the lack of validated predictive biomarkers that could help to id...
Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies [0.03%]
通过比较抗药物抗体的信噪比来评估阿达木单抗生物类似药研究中的免疫原性和互换性
Lena Lemke,Andrew Blauvelt,Ines Brückmann et al.
Lena Lemke et al.
Background: To support an interchangeability designation for Sandoz adalimumab biosimilar (GP2017), antidrug antibody (ADA) signal-to-noise (S/N) ratios were assessed in the GP2017 ADACCESS trial to directly assess potent...
Randomized Controlled Trial
Expert opinion on biological therapy. 2024 Dec;24(12):1375-1385. DOI:10.1080/14712598.2024.2428299 2024
Endoscopic endpoints in biologic clinical trials and beyond: the case for Crohn's Disease [0.03%]
内窥镜检查在生物制剂临床试验中的作用及意义——以克罗恩病为例
Marlou P M Adriaanse,Mark Löwenberg,Geert R A M D&#x;Haens
Marlou P M Adriaanse
Introduction: Standardized evaluation of endoscopic disease activity using valid, responsive and reliable instruments is crucial for optimizing the efficiency of clinical trials with therapeutic agents for Crohn's disease...
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis [0.03%]
评估利桑基珠单抗治疗中重度溃疡性结肠炎的效果
Amanda M Johnson,Edward V Loftus Jr
Amanda M Johnson
Introduction: Risankizumab (RZB) is a recombinant IgG1 humanized monoclonal antibody which selectively inhibits interleukin (IL)-23 though high-affinity binding of the p19 subunit. RZB was approved for use in Crohn's dise...